ArticleJournal of gynecologic oncology2026

Phase II randomized study of first-line carboplatin and paclitaxel in combination with pembrolizumab, followed by maintenance pembrolizumab alone or with nesuparib, in mismatch-repair proficient, advanced or recurrent endometrial cancer (PENELOPE).

Se Ik Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.